Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of DBPR108 monotherapy in type 2 diabetes mellitus
ChiCTR2000029574Phase 3Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of prusogliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Peking University First Hospital. Primary endpoint: HbA1c. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
prusogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2000029574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029574.